In hepatocellular carcinoma (HCC), AHR exerts its oncogenic effects primarily through nuclear translocation and subsequent transcriptional activation of its prototypical target gene CYP1A1, which mediates metabolic activation of procarcinogens and induces DNA damage, thereby driving tumor initiation and progression 36,37. The gene discussed is CYP1A1; the disease is neoplasm.